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Effects of Short- and Long-Term Carvedilol Administration on Rest 
and Exercisr? Hemodynamic Variables, Exercise Capacity and Clinical 
conditions in Patients With Idiopathic Dilated Cardiomyopathy 
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Activation of tbc sympahetic nervws qstcm is knmw IO be 
chmnic congAve hean failure (I-7). l3ela~odm~ergic block- 
ine aw~t~ beerwe of their abiliw IO inhibil rmrmathoadren- 
e&-drive, an thcrefm potentiilly wdul fci tic lolyknn 
Irentmcn~ d this syndrome. 
Most studies of beta-bbcken in patients with hean failure 
have been performed with mctqwdol rhenpy. Lan@m~ 
nWoprdol tbcrnpy has improved clinical dates and left wn- 
cm when started at lmv dose& in 1 Id 
of patients with heart laibuz (17.20). Clinical and hcnmrty. 
namic &t4omdon after short-term mecpmlol admbds4m- 
Bclrbbckrs wllh reDdated vwdillla u&ily have rc- 
cenlly ken inlmdwcd. Because dtwkad and prelod redw 
dun may OOUlllelset lb& Bboetcml lugaivc lnolmpic CfccI. 
~hcsc dw seem pankulmrly nd2abk for the trcamwn~ of 
@cnk with heart failurn (7). Accordiiy, beta-blacken with 
vwdllawr raiviry, such as Iabclnbl (?Z). bwiwkdol(Z3-28) 
ad n&iwbl(Z9), have been ~&II lo be well tdnated and 
8 imprwe clink4 status and Idi ventricular functim~ b 
@ents wbh cqenive hearI fnilure. 
Cmwdild is a new beta-blocker devoid d inwinsie qmpa- 
lhamimcL activity .with aocintcd vasodiitw I&IS mdi- 
rkd by alpbal-reqbx amagmdsm (7,3%31). 11 has been well 
~alcraled sbml tam (3.2) and hla imprwed symptoms, exenire 
lokrance nnd leR vm~rkulpr timcdon bngtmn (3.3) in pa- 
timk with bean failure caused by coronuy artery diswe. 
Hamw, thrrc shldirs were WI omrmlkd with placebo and 
m~lulted only patients with isclwmic hart disease in whom 
thefaw&deeUskofcarvediblmgbe relaicdtoawhution 
in myomrdial iszbemia By mnhab+ patients with idiopathic 
dilated cardiom)opr&-y may be particu!arly se&ix to the 
benetkial etTezts of beta-b&en (2734). Pre1br.i~ repxts 
(3.5-Xt) have suggested that croveditol can improve sympmrm 
and tdt wntrkutar tin&n in p&tents whh idiisL.ic dilated 
cstiomyopathy. However. data regarding its short- and long- 
term e&e& on clinical symptoms ;mml rest and excrcisc hcmo- 
dymuoic variables are lacking. 
fn this stody we evaluated. u&g a raodomized doohle- 
blind, placebosontmlled, parallel d&o. the etTects of short- 
sub&al and maximal exercix capacity and rest and ever- 
cbc hemodvnamic variables in a emoo of oartents with can- 
gestive heah failure cased by id&&ii &ted cardiomvo- 
pathy trzated with digitalis. diuretic agems and angio&in- 
mnvertiog cmymz inhiitors. 
domtion. in cli~tally~stabdr condition. with‘& ch&c their 
dug rgimco to the-month before the study. AU p&cots bad 
symp(olllitk hean f&hue (New York Hcti ?a.wcttioo func- 
tiomtclw.Uarlll). Utventticolarejection fraction C3.54 by 
& excluded l$ endomyocamml t&y in pnticnis with il 
rmnpatibte clioicut hiiory. Patknrr with a history of ntcohd 
Owe, hypertmsiou @mar, vstvolar disease or other known 
uoscs of heart fatlum were also exctuded. WC ako cxclodcd 
patients wtlh major contmbUtc&ns to hcl+hlocker therapy. 
&ch as bronchial asthma insulin-depndent diihctes mcllito.. 
&awed heart btoetc or bradvvrhvihminz Each wtient wx 
Ids or ha inhmoed written &scnt~befom entry in’w the shy. 
All pattents were trcaed with dig& and tumscmids: all. 
except I in the cawdtiil gmu~ wcrc taktng ilngtotenrin- 
amwttng eruyme iohibiton: 9 wrr also taking nitrates 
(kaswbJdc S-mononitrate. 40 mg three times B day. in all 
patcots); and 25 were t&tog snticongukmt apna Adminis- 
tration of olha kta.blockem. &tom notagonists, anttar- 
rbyihmics and hypotenstve drugs (mxcludud d&tic drugs. 
m@enrin-fling emyme inhibitors and nirmtes) was not 
allowed. 
Pmcedwa On the day before the study, a triple-lumen 
%an-Ciaaz catheter was inserted prcutaoeousty through the 
fight b~tcmal jogolu vein and positioned bt the pulmonmy 
arkry, and dn wterial cannula was ~itioo#I in the radial 
artery to mearac standard hemodynnmic rartabks. Cardiac 
nrpm was c&incd wia the thcrmcdtlution method, and 
derfwd hem&namtc vtiabtes were calculated according 10 
standard formulas (39). Bic@c cxercisc testingwas perfomxd. 
in ti smmg pasitioo, with simulmoeous gas exchange and 
hrmodynamic moeitoriog. Exercise was started at a work toad 
of 0 W, with further bwemenk of 20 W every 2 mio, at the 
wloeity of 50 rpm, up to the appearann oftbnitiog *apnea m 
fatigue. No patient had chest pain. major cmdiac arrhythmia 
or exercise-induced ST segment depression >I mm du@ the 
test. Elcctrowdiogmpbtc and rapimtmy variables were coo- 
Iinuously mwimred, hemodynamtc mes~lremcnt~ were ob- 
taincd at rest. after an eqoilibmdon period of at least LO mb& 
doti@ thelast minutedeachwmktoadhaemea andatpeak 
exercise. 
MaGmaI cxercb capacity uas evaluated as peak exercise 
dumtion and VI+ ?eak Vo, vms cakulakd averaging the tinat 
30 s of exercise. Before entry into the s&y, exercise tests were 
lrpated at 2- to 3.day immvals up to the acbiimcnt of 
rcpmduciblr results (peak Vc change benveen two cmwco. 
tiw texts rl ml& per mih). 
On a ditIercnt day, pattents also oodewcnt waloation of 
subma.im;ll exercise cam&. Tbii wax asxssed ,as the dura- 
the b&&c ;n;utimal a-x& tadsring. This rwk load wai 
rcach& after a wnrming phase of 6 min at 20 W and was 
mdnuined up to exhaostioo or a maimurn of m min. The 
vacw work load was wd in the exxobmtion pcrfomwd 
heforc and sher loog-term therapy. 
LcR ventricular ejection fraction sod wlumes were noto- 
mndcldty dctcrmincd usingeqoil~tiiom radiomtclkk wntricu- 
logmphy (JO). before and after long-term thxrapy. Clinical 
symptoms wro evaluated using functional classification and 
tk Minnesota Living nith Heart Failure (MLHF) qoestion- 
nab-e (40. 
Rwcul. A do&k-bitt parsite randomized. placebo- 
mmtrulkd dertgn was used with I:1 rrmdomhatkm to either 
oloc&~ or cxvcditot. 
’ lo the first port of the study. the short-term hcmodynamic 
cffcetx of plweboorcawedibl(12.5 mg, omlly)wcre cvnluotrd 
in hvo socce.&e days. 018 the first day. each patient underwent 
hcmodytumic monitoring at rest. in the supine position. with 
data collectrd before and I. ?. 4, 6 and 8 h after drug 
odministntion. On the oat day, pattents wea evaluated ai 
rest sod during mazimal cnrdttlmmmy exercise telling 
before and 3 h after eitha placebo or carwdilol (125 mg 
orally) ingcstioo. A lttt meal was allowed hetwen the sixth 
and the eighth hour of study on the first day. To ensore 
hemodynamt atability, diuntic and vasodtlator agents were 
sdmiohtead onty at least 16 h before each hcmodynamic 
cvalu&lo. 
Aftcr compietkm of the short-term phase of the study, 
patients resumed their osoal dose of digitalis, diuretic drugs, 
angiotmninanwtfng enzyme iobibitors and nikateS added 
to either placeha or carvcditol. Cavedilol was started at tbc 
da= of 6.R mg rwife daily with weekly ineremenk to the doses 
of 6.25 mg three times a day, 12.5 mg twioe a day, 12.5 mg thrcs 
times II day, and, last. 2.5 mg wiee a day. Five patienb weivzd 
~25 mg wice a day of carveditol because bmdycmdia (rest 
hean rate CM heats/mio in three patiWIb). hypoteoskm 
(qstollc blood prcsx- <90 mm fig in one patient) or 
bwtddal wbaing (ate patient) was noted during the weekly 
vis6.s pufomud bdore cacb dose increment. After the titm- 
lion pharc, paiena continued Lo rccefve tbe maximal dose 6x 
at lest 3 mauhs. Placebo was administered as tablets similar 
to catwdibf, using the tatne ptaml of drug admbdftion. 
Dhuctic dosage muld be adjusted a clhdcally indiated by the 
evaluation of n~ptoms and body weight dudng the hmg.term 
tleatmem phase. 
l?3ticnts WWT Kevalvated after at least 3 months of long- 
lcrm theraw with tbr maximal dpaes ol either umdilol or 
cawedilol or &ebn and 3 h after thug readministration. 
Vasudiktor sad dhtretic agents mrc not administered during 
hcmodywmic mcaswemcnts n in the pwias 16 h. 
IXnical evaluation, pcd quilitim ndlonudide ve* 
tmaphy, wlmtarimal exercise testing and nsxsmenl of 
the MLHF score WCIC repeated hefore and aftt ~-term 
therapy. 
!3hmtlal mly#h Results arc apresed s man v* 2 
SD. l-way amlyxii of viuiancc for m~tittuwr ~riablcs and 
mnthtgcilry tables lor categwic vatiabks wr4 wd to mm- 
psre be&line dmical data in the pllabo and catwdilol gmups 
and beeline data of the patients -ding and not rsspond- 
Ig to calvcdii ther@y. IWay and mpeated-meatttrcs 
Clinical f&ares of the patims randomized to receive 
nlacebz or uMdilol were IIM imdScanllu dl6brcnt (Table 1 L 
fro patient ptwnkd untoward &cts U;t catsed irug will;. 
dmwal. I)uring the titmllon pha~ one patient taking catvc- 
dilol pmscnled wonming mea that impmvcd with an 
iacre= in the hmsmdde b In Ihe lq-term tnamm 
phprc, IWO patient6 taking placebo and none kking mrwdild 
were admitted to hospital for wtscning heart failure, and 
fumsemlde daily dw was increased fmm 61 + 39 la 80 t 
78mgiotheplrcbo~pandlrmn54~4toJ7~~ay 
in the mmdilrl gratp @ - NS). 
ulwtdrbolbtemaNedibf~nlknattbcmmly. 
tumk nrponnr II s@tte rent, ShotI-temt adminimatim of 
urvedilol, 12.5 atg orally. induced. In compwiwn with pk. 
cebo, (I aignifwant t’eductlon io test heart rate and tncan 
arterial and pubttcmaty wedge pressutes with 110 chanp in the 
other varkbles (Fii. 1). No ptient had advetse eUccts or a 
dears XI% in cardiac index. 
was signllly reduced by both shotI- md loly-lcrm cave- 
dcuacd afta both shmt- and long-term amdilol admi& 
tratlca Peak cxctcls cardiac btdea dccresed sfta short-term 
catwdikl ingestion, but with m +ikmt innce’r campared 
with bwlinc after long-tam thmpj. 12 h after lat dwg 
admlnhamtion Similar IO what was obsetwd at r&, stmkc 
wlvnnandstmkcwtkindnermrcnotcbo~dlysltort- 
kfm arvcdilol ingestion andwuc f&niily impmvrd after 
long-term thcmpy. Rlghl atrial. mean @ttmttaty artctial and 
padnttntaty wedge prcssurex &clincd aftw slmrt-term dtug 
in#ia, with. hlttber dccreue alter Icaphmt thcnpy. 
Nlwlavuhr evlltulba, Left vmtricttk ejcctim fratiM 
wan tan slgnilimnlly changed by long-temt placebo *l.tis 
Iration (fmtn 2C 2 6 to 19 + 5%) although it incrca& 
signbican~ fmm 20 f 7 Ia 30 * 12% (p < o.llmll) aLa: 
bng-bzrm catwdilol adminktration: indivihul chaypr are 
shown in Fiim 3.l.A vnIrktdar enddk5toiic vdume was 
not changed rigIdScantly by ltnt6+rm camAiM adminima- 
lien(hrm160+4810153~46m~z~plaeeboudfrom 
151+ 53 to 143 f 51 nUm* after caivcdild therapy). 
.. bth hnctimml kiss and quality of iii, &s&d by the 
MUIF qoemimmaire, +dlicantly improved after long-term 
cawedibl uMoistration compared with placebo (Fig. 5). 
AL!&lde ClmnSes iii MLHF sare mm not riSracmuly mrre- 
patimtr were as&&d to two ~&IS. We defined as gDod 
Moonden oatients who had an increase >3 absolute units in 
lell’ vert&lar ejatlon fmciion and >180 s in submaximal 
exercise duration after long-term therapy. ‘&SC wduep were 
chosen because they were X2 SD beyond the chan.Se oCwve.d 
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in the placebo group. By these criteria, 14 @enis were pd 
reqtondwr, and 6 patimts vtae MI. No variable meunucd at 
beIw.enthese IWO 6mupsexcqt ta1~c6ilol dose, which tended 
basclbw and al re81 and peak aexcise diked s&dfim 
ta bc higher in the patients with a !korabJe aspomc to 
therqy (p - 0.05) (TabJe 4). 
Discussion and OR mnsismt with previous studies performed using 
S&Mum awedilol &dtdskatka and bclmdpamk beta-blockers with vasodikmr activity (23&W). In contrast, 
e&t& Guwdibl ingestion induced a signilicant redwtion in tb8 sbott-term athtdni8rt-dtica of metopmlol caused a r&c- 
burc mk acd auaa at&J and ptdmo~ty wedge pref-surcs don in cardii index with no sigtdiicant change in left ventrio 
with M adwrse e&t4 on any bm&ytmmic vatkbk. Thcsz ular filling pleasrne (15,21,42,43), and, in some shtdics (21). an 
tatits aplain its good toktat4liq dutiug the titration phase increze in systemk vascular esistma. 
Our study does not make it possibk to crtablkh the 
meEhaninm by which short-lerm mwedibl dwtwed pllmo. 
nary wed& p~~run. ‘fhk c&t might b! ml&d to its 
alpha,-antagonist anivity becaw peripheral vsndibtion may 
deercam pulmonary W.-&C pressure both thmq# a reduubn 
of prcload and. indirectly, tkmugh I rcdttctbn of mitral 
d. patients with d&d cardiomy&thy, the prcvalmcc of 
mitral regurgitation h high (44X and dcpmdencc of relax&n 
on left ventricular prewrc and sftedoad is enhanced (45). 
Corcomitant mechanisms may be represented by prolongation 
ILMI. 
of the Ailing time tkmu$ hat rate rbwing (4S) (II better 
wntticuloattcrial cmtplhtg, or botk (4% 
ular ftmctioli. both at rest nd hiring maximal &ercisc, witk a 
significant increase in cardiac stmkc volume and stroke wotk 
indarn accompanied by a tzdwtbn in t@ht and left vettttb 
ular dllbg fwewrcr. 
durinp aucise in only a few studies (24,46,47\ et 
al. (44.47) found mt innrarc In peak eamzim cm-dku, amkc 
volttmc and stmke work in&m aRet k%?l_twnt metqmbl 
therapy. fimwwr, their rcsttlts UC Mimic to compare vdth 
otm because meauwtncttts mtx atfomrd at a fixed utb 
mwimsl wk bad. and tkc lest d&g w withkeld 24 h t&we 
each cvsluatbn in their studii (46,47). Out results an aimiku 
to thmc of Polkxk et al. (24). wlm evaluated peak act& 
F@n 3, lndividwl cllangg In left wtttbdar 
cjztion fmtinn (LV EF) after lung4em treat- 
ment whh ptaccbo (qm rbrkr [kft), and 
rynduol (satu ctrdm [Ii&q). 
bemwJynamic vmirablcs befun mul after lung-term bucindtdol 
Lempy. 
Our raulls du nui make il pumiile to dmw wnclunionr 
rcgatding the mechanism uf action of cmwdilol bx~usc we 
did not amess v&bks independent of luadii conditkmr 
Hwcvcr. an improvement in myawdial furwtion seems likely 
because the left venniculnr 6mctbm cuwc was shifted upwrrd 
and to the I& mui ejection fraction impmad with nu 
signilkant change in left vmwicular end-diawlic vulume md 
only I sliiht reductkm in ryrtemic wculttr rcristance ufter 
bx+term carwdilol therapy. Momover. rupid developmum of 
tokmocc to the vasodilatw bets of rlpha,-antagonists bar 
been widely descrfbed (48-50). and it seems unlikely that 
hem-blockerr can prevent it (51). An ndditiomd mechwirm of 
action of mwcdilol might be the reduction of mitral regurgi- 
mtiw hovwcr. Doppler ecboeardiigmp::ly was nm regularly 
pcrfurmed in our patients. 
WC alw tested the elkcts uf awdilvl madminiwmion 
after long-term therapy. Cmwdilol madministmtioo both at 
rest and at pea exwci.w produced u furtbcr reduction in heart 
mtc with a comequent decline in cm&c index Tbex dntu are 
wnsistent with recent results obtained using mespmlul(52) 
and show that tbw agents maintain their beta-blucking activ- 
ily in heart failure wen lur km@m therapy. Unlike what 
nib obwwd aher short-term drug ;Idmkdktmtiun. ret pul- 
munx) pwsuws were nut changed, and s}stcmic vascular 
rcs~tmux fended to increase. taller the nrxt cmwdilol dose. 
Tbw rccults arc mnriam~t with the dev&pmcm of tolmance 
fu the wsudilstm ulphu,-untagonist activity of thiv drug. 
Ctbdwl syap~oms and amrise capr&y. In OUT study. 
derpitc the signilic~nt impmwncm in kRvcntricukufunction. 
cxvcdilol theraW did nut signilicmuly change pak rwcise 
mpacity. musrurcd as peak cwcisr dumtion and peak Vu:. 
Ecra~sc thcx vmiablcs are hiibly rclatcJ w the peak exmrise 
cardiac il?dex (S346). their lack of cbunge is likely caused by 
the mnwmi~ant mductkm in pak cxcrcise heart mte. Accord- 
ingly. pwk cxcrcisc capacity did nut cbangc in studiis in which 
bct;l-hlwkea decreased peak excxcisc bawl mtc’ (lb.LJ.27- 
29). wlwx it improwd when peak heart rate w& not reduced 
(11.46). A diren wrmlation between the change in peak 
cwcisc hart rate and the chnngc in peak cwcix duration 
after bucindalal thimpy bus hen described (26). The incmuse 
beaus un$b&nts with cortmmy artmy d&w were stud- 
ied. 
A highly rignidmnt mcrem~nt m submaximal exercim du- 
mtiun ws found ler long-term muvedilol thcmpy. This result 
is consistem with the impmvcmcnt in ktl ventrfcular function 
uhtuiwd with thisdrugund with the hypoth& lhot bluntinguf 
peak exerck~ hem? fatewar the main mcchunism of the lack of 
imprwrmcnt of peak exeti tokmncc. Simikw rcwlts were 
fmmd in another eport (26). The improvement in rubmaimal 
crcrck t~lcrxnce was ilcmmprnied by md correlated with an 
impruwmcnt in qwlity of life. measured as Ihe MLHF smrr 
Predtction dtk re~paee to tbenpy. Similar to what was 
obrcwcd with other drugs. the mspon?e to ktabkxker tbcr- 
spy is nut humogcncous in patientswith heart failure. Etkdugy 
hud u ri~nificunt mk in sumc stud& (27). and we evulwted 
mdy p;rtientr with idiiprdhic dilated cardiomyopathy to avoid 
the intlucvm of this vmiabk. In uur study, no baseline vminbk 
wil* ~mdiitivc of the mspansc to thcmpy. Tbeae rcmd~ ore in 
uccuxkmce with previous tudies (9.13) but ditTer from others 
in which a high I& heart mtc ad mom adw~~I left wmri~lttr 
dy,tipctkm wre bund to bc reInted with u fnwmble raps IO 
betahkxkadr (I I). 
Cm,dusfm~s. Ourntudy~uws that shoti-term therapy with 
the ka.bluckcr and vasodilatur cmwdilul tiwcs a reduction 
in hcut rate and mean amid and MI wnlrkulu Rlling 
pm with no signifiml change In lhc Uha bemody- 
namicwiablc.s,md thm kmg4ermthmapysbmwa~lgniik~t 
improvement in .%mke vobune and rlmkc work indRn and 
kf~ vemriculu cjatica fmmlon, with I finthcr nductbn in 
bcmi rate and dgbt atrial and pulm~lmy wc@c pnmnres 
l’helhcahemcdpmkcban~eaareprcmntboihmntiand 
dluing mnximal exmck. Peek crerck capacity is not sipI& 
audly akcted by either short- or kmg-lmm wvedikd admin. 
Ymdon, wiwer a al@ieati impwnem in clinical spnp 
IOK., quality d life and rubmaximll eaenise duntbn VP 
&k&d afler lon@xm tbcmpy. No bamlinc vtiabka prmit 
pwJiin of the rspnle to therapy. 
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